Clinical Trial Update: CMV Glycoprotein B Vaccine in Allograft Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a cytomegalovirus glycoprotein B vaccine in allogeneic transplant recipients is ongoing; current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• CMV glycoprotein B vaccine (glycoprotein B vaccine)

Snippet

Sponsor: University College, London | Conditions: Cytomegalovirus Infections | Phase 2 | Status: UNKNOWN